Four Weeks Treatment with Glecaprevir/Pibrentasvir + Ribavirin—A Randomized Controlled Clinical Trial

Enhancing treatment uptake for hepatitis C to achieve the elimination goals set by the World Health Organization could be achieved by reducing the treatment duration. The aim of this study was to compare the sustained virological response at week 12 (SVR12) after four weeks of glecaprevir/pibrentasv...

Descripción completa

Detalles Bibliográficos
Autores principales: Madsen, Lone W., Christensen, Peer B., Hansen, Janne F., Røge, Birgit T., Holm, Dorte K., Dröse, Sandra, Øvrehus, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8948928/
https://www.ncbi.nlm.nih.gov/pubmed/35337021
http://dx.doi.org/10.3390/v14030614

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8948928/
https://www.ncbi.nlm.nih.gov/pubmed/35337021
http://dx.doi.org/10.3390/v14030614

Ejemplares similares